Fig. 2

Western blotting (WB) analysis of the cortex (a, b) and hippocampus (c, d) tissues from Winstar rats infected with PM under vitB6 pre-supplementation treatment: a Significant reduction in the expression of APE1 is observed in the CX/20 h in the PM/pre sup vitB6 animals compared to the PM animals; b In the CX/24 h, WB from infected animals showed different sizes of APE1 (37 and 70 kDa) which resulted in a higher expression as compared to the control group as observed in a; c In HC/20 h, a significant increase in APE1 protein level was observed in the PM animals compared to the CTRL groups; d WB from the HC showed a cleaved form of APE1 in some infected animals which was not detected in the lysates from animals which received vitB6. β-actin was measured as the loading control and was used for data normalization. Data are reported as the mean percentage relative to control of each time point ± SEM. Groups for the CX: uninfected control animals (CTRL) 20 h (n = 5), uninfected control animals (CTRL) 24 h (n = 3), infected animals (PM) without vitB6 treatment 20 h p.i. (n = 5), infected animals (PM) without vitB6 treatment 24 h p.i. (n = 3), infected animals plus vitB6 treatment (PM/pre sup vitB6) 20 h p.i. (n = 9), and infected animals plus vitB6 treatment (PM/pre sup vitB6) 24 h p.i. (n = 3). Groups for the HC: uninfected control animals (CTRL) 20 h (n = 3), uninfected control animals (CTRL) 24 h (n = 3), infected animals (PM) without vitB6 treatment 20 h p.i. (n = 5), infected animals (PM) without vitB6 treatment 24 h p.i. (n = 3), infected animals plus vitB6 treatment (PM/pre sup vitB6) 20 h p.i. (n = 4), and infected animals plus vitB6 treatment (PM/pre sup vitB6) 24 h p.i. (n = 3)